HSP90既是细胞应激反应的生物标志物,也是细胞内重要的分子伴侣蛋白。HSP90调控的很多客户蛋白,如EGFR、Met、Raf-1、IKK、p53等,均与肿瘤等疾病的发生和发展关系密切。HSP90抑制剂通过与靶点结合抑制其活性,导致其客户蛋白无法正确折叠而降解,可从多环节多途径影响细胞生物学效应,因此HSP90抑制剂在肿瘤治疗等领域展示出良好应用前景。本文将对近年来重要的小分子HSP90-N端抑制剂的研究进展进行综述。
HSP90, which is the biomarker of cell stress and endogenous protective protein, functions as a molecular chaperone. Many client proteins of HSP90, including EGFR, Met, Raf-1, IKK and p53, play important roles in the occurrence and development of tumor. Binding of HSP90 inhibitors triggers the deactivation of HSP90, resulting in client protein degradation, and hence inhibits the tumor growth by blocking multiple targets involved in signaling of tumor proliferation. This review summarizes recent development of small molecule inhibitors bound to N-terminal of HSP90.